Logo image of BPMC

BLUEPRINT MEDICINES CORP (BPMC) Stock Fundamental Analysis

NASDAQ:BPMC - Nasdaq - US09627Y1091 - Common Stock - Currency: USD

94.35  +0.28 (+0.3%)

After market: 94.35 0 (0%)

Fundamental Rating

3

Overall BPMC gets a fundamental rating of 3 out of 10. We evaluated BPMC against 571 industry peers in the Biotechnology industry. BPMC may be in some trouble as it scores bad on both profitability and health. BPMC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year BPMC has reported negative net income.
BPMC had a negative operating cash flow in the past year.
BPMC had negative earnings in 4 of the past 5 years.
BPMC had negative operating cash flow in 4 of the past 5 years.
BPMC Yearly Net Income VS EBIT VS OCF VS FCFBPMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

BPMC has a better Return On Assets (-5.69%) than 89.17% of its industry peers.
The Return On Equity of BPMC (-22.46%) is better than 83.84% of its industry peers.
Industry RankSector Rank
ROA -5.69%
ROE -22.46%
ROIC N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
BPMC Yearly ROA, ROE, ROICBPMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

BPMC has a better Gross Margin (96.04%) than 96.63% of its industry peers.
In the last couple of years the Gross Margin of BPMC has grown nicely.
The Profit Margin and Operating Margin are not available for BPMC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
BPMC Yearly Profit, Operating, Gross MarginsBPMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BPMC has more shares outstanding
Compared to 5 years ago, BPMC has more shares outstanding
The debt/assets ratio for BPMC is higher compared to a year ago.
BPMC Yearly Shares OutstandingBPMC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BPMC Yearly Total Debt VS Total AssetsBPMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 1.55, we must say that BPMC is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.55, BPMC is doing good in the industry, outperforming 68.92% of the companies in the same industry.
BPMC has a Debt/Equity ratio of 1.15. This is a high value indicating a heavy dependency on external financing.
BPMC has a Debt to Equity ratio of 1.15. This is amonst the worse of the industry: BPMC underperforms 80.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.15
Debt/FCF N/A
Altman-Z 1.55
ROIC/WACCN/A
WACC10.28%
BPMC Yearly LT Debt VS Equity VS FCFBPMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

BPMC has a Current Ratio of 2.85. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
BPMC has a Current ratio of 2.85. This is in the lower half of the industry: BPMC underperforms 67.50% of its industry peers.
BPMC has a Quick Ratio of 2.80. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.80, BPMC is not doing good in the industry: 65.72% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.85
Quick Ratio 2.8
BPMC Yearly Current Assets VS Current LiabilitesBPMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

BPMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.55%, which is quite impressive.
Looking at the last year, BPMC shows a very strong growth in Revenue. The Revenue has grown by 103.97%.
The Revenue has been growing by 50.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)54.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.59%
Revenue 1Y (TTM)103.97%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%103.41%

3.2 Future

BPMC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.82% yearly.
The Revenue is expected to grow by 26.56% on average over the next years. This is a very strong growth
EPS Next Y69.57%
EPS Next 2Y51.35%
EPS Next 3Y45.38%
EPS Next 5Y34.82%
Revenue Next Year42.68%
Revenue Next 2Y37.65%
Revenue Next 3Y34.43%
Revenue Next 5Y26.56%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BPMC Yearly Revenue VS EstimatesBPMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
BPMC Yearly EPS VS EstimatesBPMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BPMC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BPMC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BPMC Price Earnings VS Forward Price EarningsBPMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPMC Per share dataBPMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as BPMC's earnings are expected to grow with 45.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.35%
EPS Next 3Y45.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BPMC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (2/20/2025, 8:01:46 PM)

After market: 94.35 0 (0%)

94.35

+0.28 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners106.45%
Inst Owner Change4.19%
Ins Owners0.82%
Ins Owner Change-2.08%
Market Cap5.99B
Analysts80
Price Target129.2 (36.94%)
Short Float %6.7%
Short Ratio4.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.16%
Min EPS beat(2)-10.05%
Max EPS beat(2)9.73%
EPS beat(4)3
Avg EPS beat(4)15.27%
Min EPS beat(4)-10.05%
Max EPS beat(4)39.24%
EPS beat(8)7
Avg EPS beat(8)14.87%
EPS beat(12)10
Avg EPS beat(12)10.07%
EPS beat(16)12
Avg EPS beat(16)-6.62%
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.61%
Max Revenue beat(2)-1.07%
Revenue beat(4)2
Avg Revenue beat(4)11.31%
Min Revenue beat(4)-1.61%
Max Revenue beat(4)30.77%
Revenue beat(8)6
Avg Revenue beat(8)16.72%
Revenue beat(12)9
Avg Revenue beat(12)20.69%
Revenue beat(16)12
Avg Revenue beat(16)16.8%
PT rev (1m)0.34%
PT rev (3m)-1.06%
EPS NQ rev (1m)-0.88%
EPS NQ rev (3m)-4.05%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-0.28%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.52%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.78
P/FCF N/A
P/OCF N/A
P/B 20.07
P/tB 20.07
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-3.1
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS8.01
BVpS4.7
TBVpS4.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.69%
ROE -22.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.04%
FCFM N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score2
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 1.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.42%
Cap/Sales 0.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.85
Quick Ratio 2.8
Altman-Z 1.55
F-Score2
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.59%
EPS Next Y69.57%
EPS Next 2Y51.35%
EPS Next 3Y45.38%
EPS Next 5Y34.82%
Revenue 1Y (TTM)103.97%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%103.41%
Revenue Next Year42.68%
Revenue Next 2Y37.65%
Revenue Next 3Y34.43%
Revenue Next 5Y26.56%
EBIT growth 1Y56.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.03%
EBIT Next 3Y46.14%
EBIT Next 5Y36.83%
FCF growth 1Y56.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.91%
OCF growth 3YN/A
OCF growth 5YN/A